Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,208 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Powder Clear all

Conditions: Asthma
Interventions: OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo; Drug
Lead sponsor: Oriel Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 879 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 47
States / cities: Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more

Conditions: Skin Sagging, Skin Wrinkling, Skin Dryness
Interventions: Ovolux brand eggshell membrane powder, Placebo; Dietary Supplement
Lead sponsor: ESM Technologies, LLC; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: FB-001, Placebo; Biological
Lead sponsor: Federation Bio Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dysphagia
Interventions: Cold Thin Liquid Barium; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 43 Weeks
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Ileal Pouch
Interventions: EXE-346, Placebo; Biological · Other
Lead sponsor: Exegi Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more

Conditions: Shingles, Herpes Zoster Infection, Human
Interventions: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 35
States / cities: Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Human Insulin Inhalation Powder, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 24
States / cities: Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 110
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more

Conditions: Basal Cell Carcinoma
Interventions: STP705; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Metabolic Syndrome X
Interventions: Freeze-dried Whole Grape Powder, Grape Powder Placebo; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 30 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Homocystinuria
Interventions: SYNB1353; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions: Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Healthy
Interventions: Selpercatinib; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 529 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more

Conditions: Asthma
Interventions: L-citrulline; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Nutritional Physiological Phenomena, Obesity
Interventions: Sugar Sweetened Solid Treatment, Sugar Sweetened Beverage Treatment; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Idiopathic Parkinson's Disease
Interventions: CVT-301; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 30 Years to 86 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 55
States / cities: Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI, TIO/OLO, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more

Conditions: Pulp Necrosis, Regeneration
Interventions: Triple Antibiotic Paste, Standard Treatment; Drug · Other
Lead sponsor: Kenneth Hargreaves; Other
Eligibility: 6 Years to 20 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Loma Linda, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Photodamaged Skin, Volume Deficiency of the Midface
Interventions: Sculptra and Alastin Restorative Skin Complex, Sculptra and CeraVe Daily Moisturizing Lotion; Combination Product
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 41
States / cities: Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more

Conditions: Major Depressive Disorder
Interventions: L-Leucine, Maltodextrin; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Blood Loss, Surgical
Interventions: Arista; Drug
Lead sponsor: Virtua Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Asthma
Interventions: Albuterol MDPI, Placebo, ProAir HFA inhaler; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 51
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more

Search by objective public record fields.

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

Ovolux Beauty From Within Trial#2

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

The Effects of Cold Liquids on the Swallowing Mechanism in Preterm Infants

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics

The DEB Pilot Study

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots

A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator with a Skincare Regimen

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Rapid Antidepressant Effects of Leucine

Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics